Roche aims to ‘underwhelm’ on SMA drug price to challenge rivals
Spinraza's list price is $750,000 in the first year, and $375,000 thereafter, while Novartis's gene therapy for the genetic muscle…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.